Text Size
34 studies found for:    " December 08, 2010":" January 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
" December 08, 2010":" January 07, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
2 Completed
Has Results 		Two Approaches to Routine HIV Testing in a Hospital Emergency Department
Condition: HIV Infections
Interventions: Procedure: Oral HIV screening;   Procedure: Fingerstick HIV screening
3 Unknown † Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Condition: HIV Infection
Intervention: Biological: Fluzone®
4 Unknown † Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
Conditions: HIV Infections;   Liver Toxicity;   Hepatitis Co-infection
Intervention:
5 Completed The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Condition: HIV Infection
Intervention: Drug: Efavirenz
6 Completed Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines
Condition: HIV Infections
Interventions: Biological: Adjuvanted GSK investigational HIV vaccine formulation 1;   Biological: Adjuvanted GSK investigational HIV vaccine formulation 2;   Biological: Ad35 investigational HIV vaccine;   Biological: Placebo (saline)
7 Completed TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Raltegravir
8 Completed The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Condition: HIV Infection
Intervention: Drug: Efavirenz
9 Unknown † Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Condition: HIV Infection
Interventions: Drug: Aprepitant;   Drug: Aprepitant placebo
10 Active, not recruiting Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine;   Biological: IL-12;   Other: Placebo
11 Active, not recruiting Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
12 Unknown † Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin
13 Active, not recruiting Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo
14 Recruiting Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Condition: HIV Dementia
Intervention: Drug: Atorvastatin
15 Active, not recruiting TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV
Condition: HIV-1 Infections
Interventions: Drug: Darunavir;   Drug: ritonavir
16 Suspended A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Condition: Human Immunodeficiency Virus I Infection
Interventions: Drug: GSK1349572;   Drug: GSK2248761
17 Active, not recruiting A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Dolutegravir;   Drug: Atripla;   Drug: Abacavir/Lamivudine;   Drug: Abacavir/Lamivudine Placebo;   Drug: Dolutegravir placebo;   Drug: Atripla placebo
18 Completed Recovery Management Intervention in China
Conditions: Methadone;   HIV Infections
Intervention: Behavioral: Recovery management
19 Completed Pilot Study of Metabolic Syndromes and HIV Infections in Indian Tibetans
Conditions: Metabolic Syndromes;   HIV Infection
Intervention:
20 Completed A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Efavirenz
To Top

Previous Page Studies Shown (1-20) Next Page (21-34) Show next page of results
† Indicates status has not been verified in more than two years